Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

DNDN

97 Posts
Pagina: «« 1 2 3 4 5 | Laatste | Omlaag ↓
  1. [verwijderd] 5 november 2011 12:48
    Deze link is leuk, nou ja leuk, zoals ik al eerder schreef, Gold en zijn Kornuiten hebben dus flink gecasht, nu weet ik ook precies hoeveel namelijk voor maar liefst ruim 83 miljoen $.
    Moet je maar eens door heen bladeren, ook het aantal bonus aandelen wat ze elkeaar toegeschoven hebben is om missleijk van te worden!
    Het bedrijf heeft nog nooit 1 dollar winst gemaakt, en de hele top heeft zijn zakken al volgeladen en zijn allen schatrijk!
    En wij in Nederland hebben het steeds over de Balkenende norm, lachwekkend als je dit vergelijkt!!
    Ik vind het ronduit crimineel!

    www.secform4.com/insider-trading/1107...
  2. [verwijderd] 5 januari 2012 21:24
    Dendreon announces higher revenues, stock rises
    .Puget Sound Business Journal by Valerie Bauman, Staff Writer
    Date: Thursday, January 5, 2012, 11:15am PST

    Dendreon Corp. announced gross revenues of $82 million for the fourth quarter, up from $25 million in the fourth quarter the previous year, but did not reveal its quarterly or annual net income.

    Officials at Seattle-based Dendreon (Nasdaq: DNDN) produced the early product-revenue numbers for participation in a JPMorgan health care conference next week. The biotech company did not plan to reveal net revenues until its earnings call with analysts next month.

    The early news that the company did share was positive. Dendreon also reported $228 million in full-year gross revenues from its prostate cancer drug Provenge. The company's stock rose nearly 40 percent by Thursday afternoon, rising from $7.60 to $10.59 per share.

    Sales of Provenge and the incomplete fourth quarter results were positive and contradicted earlier statements from Dendreon advising investors to expect "modest" quarter-over-quarter growth.

    “We had a strong fourth quarter that exceeded our expectations,” said Mitchell Gold, president and CEO of the company. “As we look to 2012, we expect modest quarter-over-quarter growth while we focus on bringing additional clinics on board and converting them into steady prescribers.”

    The company had challenges selling the immune-boosting cancer drug when doctors balked at prescribing the immune-boosting cancer drug because of its high cost – about $93,000 per patient.

    In September, Dendreon laid off 500 Seattle employees – 20 percent of its work force.

    www.bizjournals.com/seattle/news/2012...

    Dendreon Corporation(NasdaqGS: DNDN )

    Real Time 10.61 +3.01 (39.61%) 3:12PM EST jan 5 2012

97 Posts
Pagina: «« 1 2 3 4 5 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 869,22 -0,55%
EUR/USD 1,0713 +0,15%
FTSE 100 8.060,21 +0,25%
Germany40^ 17.901,00 -1,04%
Gold spot 2.336,02 +0,86%
NY-Nasdaq Composite 15.712,75 +0,10%

Stijgers

UNILEV...
+5,45%
RENEWI
+3,78%
B&S Gr...
+2,64%
Fugro
+2,62%
Flow T...
+2,36%

Dalers

ADYEN NV
-17,67%
VIVORY...
-6,15%
Alfen ...
-5,72%
WDP
-5,24%
HEIJMA...
-3,19%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links